



2215 Yukon St .
Vancouver, BC
Canada, V5Y 0A1
T 1. 604.559.9005
abcellera.com

NEWS RELEASE

AbCellera to Report Full Year 2023 Financial Results on February 20, 2024

1/23/2024

VANCOUVER, British Columbia--(BUSINESS WIRE)-- **AbCellera** (Nasdaq: ABCL) will announce its full year 2023 financial results on Tuesday, February 20, 2024, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day.

A live audio webcast of the earnings conference may be accessed through a link that will be posted on **AbCellera's Investor Relations website**. A replay will be available through the same link following the conference call.

About AbCellera Biologics Inc.

AbCellera is breaking the barriers of conventional antibody discovery to bring better medicines to patients, sooner. AbCellera's engine integrates expert teams, technology, and facilities with the data science and automation needed to propel antibody-based medicines from target to clinic in nearly every therapeutic area with precision and speed. AbCellera provides innovative biotechs and leading pharmaceutical companies with a competitive advantage that empowers them to move quickly, reduce cost, and tackle the toughest problems in drug development. For more information, please visit **www.abcellera.com**.

Inquiries

Media: Kathleen Reid; **media@abcellera.com**, +1(604)724-1242

Business Development: Murray McCutcheon, Ph.D.; **bd@abcellera.com**, +1(604)559-9005

Investor Relations: Melanie Solomon; **ir@abcellera.com**, +1(778)729-9116

Source: AbCellera Biologics Inc.